The effect of nanoparticle size on the probability to cross the blood-brain barrier: an in-vitro endothelial cell model

Journal of Nanobiotechnology

Rachela Popovtzer²  Jean-Paul M Lellouche¹  Menachem Motiei²  Koby Baranes²  Anat Sharon¹  Malka Shilo² 

[1] The Department of Chemistry & the Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat Gan 52900, Israel;Faculty of Engineering & the Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat Gan 52900, Israel

关键词: Nanoparticle size;    bEnd.3 cells;    Barbiturate;    Gold Nanoparticles;    Blood-brain Barrier;   

Others  :  1137460
DOI  :  10.1186/s12951-015-0075-7

 received in 2014-11-21, accepted in 2015-01-31,  发布年份 2015

【 摘 要 】

Background

During the last decade nanoparticles have gained attention as promising drug delivery agents that can transport through the blood brain barrier. Recently, several studies have demonstrated that specifically targeted nanoparticles which carry a large payload of therapeutic agents can effectively enhance therapeutic agent delivery to the brain. However, it is difficult to draw definite design principles across these studies, owing to the differences in material, size, shape and targeting agents of the nanoparticles. Therefore, the main objective of this study is to develop general design principles that link the size of the nanoparticle with the probability to cross the blood brain barrier. Specifically, we investigate the effect of the nanoparticle size on the probability of barbiturate coated GNPs to cross the blood brain barrier by using bEnd.3 brain endothelial cells as an in vitro blood brain barrier model.

Results

The results show that GNPs of size 70 nm are optimal for the maximum amount of gold within the brain cells, and that 20 nm GNPs are the optimal size for maximum free surface area.

Conclusions

These findings can help understand the effect of particle size on the ability to cross the blood brain barrier through the endothelial cell model, and design nanoparticles for brain imaging/therapy contrast agents.

【 授权许可】

   
2015 Shilo et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

【 参考文献 】

• [1]Van Rooy I, Cakir-Tascioglu S, Hennink WE, Storm G, Schiffelers RM, Mastrobattista E: In vivo methods to study uptake of nanoparticles into the brain. Pharm Res 2011, 28:456-471.
• [2]Abbott NJ, Patabendige AAK, Dolman DEM, Yusof SR, Begley DJ: Structure and function of the blood-brain barrier. Neurobiol Dis 2010, 37:13-25.
• [3]Pangalos MN, Schechter LE, Hurko O: Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nat Rev Drug Discov 2007, 6:521-532.
• [4]Denora N, Trapani A, Laquintana V, Lopedota A, Trapani G: Recent advances in medicinal chemistry and pharmaceutical technology–strategies for drug delivery to the brain. Curr Top Med Chem 2009, 9:182-196.
• [5]Roney C, Kulkarni P, Arora V, Antich P, Bonte F, Wu A, et al.: Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer’s disease. J Control Release 2005, 108:193-214.
• [6]Svenson S, Prud’homme RK: Multifunctional nanoparticles for drug delivery applications. Springer US, Boston, MA; 2012.
• [7]Arvizo R, Bhattacharya R, Mukherjee P: Gold nanoparticles: opportunities and challenges in nanomedicine. Expert Opin Drug Deliv 2010, 7:753-763.
• [8]Kaur IP, Bhandari R, Bhandari S, Kakkar V: Potential of solid lipid nanoparticles in brain targeting. J Control Release 2008, 127:97-109.
• [9]Lockman PR, Mumper RJ, Khan MA, Allen DD. Nanoparticle technology for drug delivery across the blood-brain barrier. 2002.
• [10]Singh R, Lillard JW: Nanoparticle-based targeted drug delivery. Exp Mol Pathol 2009, 86:215-223.
• [11]Shilo M, Motiei M, Hana P, Popovtzer R: Transport of nanoparticles through the blood-brain barrier for imaging and therapeutic applications. Nanoscale 2014, 6:2146-2152.
• [12]Jakobsohn K, Motiei M, Sinvani M, Popovtzer R: Towards real-time detection of tumor margins using photothermal imaging of immune-targeted gold nanoparticles. Int J Nanomedicine 2012, 7:4707-4713.
• [13]Sperling RA, Rivera Gil P, Zhang F, Zanella M, Parak WJ: Biological applications of gold nanoparticles. Chem Soc Rev 2008, 37:1896-1908.
• [14]Dykman LA, Khlebtsov NG: Gold nanoparticles in biology and medicine: recent advances and prospects. Acta Nat 2011, 3:34-55.
• [15]Ghosh P, Han G, De M, Kim CK, Rotello VM: Gold nanoparticles in delivery applications. Adv Drug Deliv Rev 2008, 60:1307-1315.
• [16]Zhang G, Yang Z, Lu W, Zhang R, Huang Q, Tian M, et al.: Influence of anchoring ligands and particle size on the colloidal stability and in vivo biodistribution of polyethylene glycol-coated gold nanoparticles in tumor-xenografted mice. Biomaterials 2009, 30:1928-1936.
• [17]Giljohann DA, Seferos DS, Daniel WL, Massich MD, Patel PC, Mirkin CA: Gold nanoparticles for biology and medicine. Angew Chem Int Ed Engl 2010, 49:3280-3294.
• [18]Schroedter A, Weller H: Ligand design and bioconjugation of colloidal gold nanoparticles. Angew Chem Int Ed Engl 2002, 41:3218-3221.
• [19]Sperling RA, Parak WJ: Surface modification, functionalization and bioconjugation of colloidal inorganic nanoparticles. Philos Transact A Math Phys Eng Sci 2010, 368:1333-1383.
• [20]Shilo M, Reuveni T, Motiei M, Popovtzer R: Nanoparticles as computed tomography contrast agents: current status and future perspectives. Nanomedicine (Lond) 2012, 7:257-269.
• [21]Curry T, Kopelman R, Shilo M, Popovtzer R: Multifunctional theranostic gold nanoparticles for targeted CT imaging and photothermal therapy. Contrast Media Mol Imaging 2014, 9:53-61.
• [22]Wang H, Zheng L, Guo R, Peng C, Shen M, Shi X, et al.: Dendrimer-entrapped gold nanoparticles as potential CT contrast agents for blood pool imaging. Nanoscale Res Lett 2012, 7:190. BioMed Central Full Text
• [23]Reuveni T, Motiei M, Romman Z, Popovtzer A, Popovtzer R: Targeted gold nanoparticles enable molecular CT imaging of cancer: an in vivo study. Int J Nanomedicine 2011, 6:2859-2864.
• [24]Kim D, Park S, Lee JH, Jeong YY, Jon S: Antibiofouling polymer-coated gold nanoparticles as a contrast agent for in vivo X-ray computed tomography imaging. J Am Chem Soc 2007, 129:7661-7665.
• [25]Chithrani BD, Ghazani AA, Chan WCW: Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett 2006, 6:662-668.
• [26]Osaki F, Kanamori T, Sando S, Sera T, Aoyama Y: A quantum dot conjugated sugar ball and its cellular uptake. On the size effects of endocytosis in the subviral region. J Am Chem Soc 2004, 126:6520-6521.
• [27]Malugin A, Ghandehari H: Cellular uptake and toxicity of gold nanoparticles in prostate cancer cells: a comparative study of rods and spheres. J Appl Toxicol 2009, 30:212-217.
• [28]Trono JD, Mizuno K, Yusa N, Matsukawa T, Yokoyama K, Uesaka M: Size, concentration and incubation time dependence of gold nanoparticle uptake into pancreas cancer cells and its future application to X-Ray Drug Delivery System. J Radiat Res 2011, 52:103-109.
• [29]Chithrani DB: Intracellular uptake, transport, and processing of gold nanostructures. Mol Membr Biol 2010, 27:299-311.
• [30]Camós S, Mallolas J: Experimental models for assaying microvascular endothelial cell pathophysiology in stroke. Molecules 2010, 15:9104-9134.
• [31]Brown RC, Morris AP, O’Neil RG: Tight junction protein expression and barrier properties of immortalized mouse brain microvessel endothelial cells. Brain Res 2007, 1130:17-30.
• [32]Wagner S, Zensi A, Wien SL, Tschickardt SE, Maier W, Vogel T, et al.: Uptake mechanism of ApoE-modified nanoparticles on brain capillary endothelial cells as a blood-brain barrier model. PLoS One 2012, 7:e32568.
• [33]Orive G, Ali OA, Anitua E, Pedraz JL, Emerich DF: Biomaterial-based technologies for brain anti-cancer therapeutics and imaging. Biochim Biophys Acta 1806, 2010:96-107.
• [34]Wong AD, Ye M, Levy AF, Rothstein JD, Bergles DE, Searson PC: The blood-brain barrier: an engineering perspective. Front Neuroeng 2013, 6:7.
• [35]Tosi G, Fano RA, Bondioli L, Badiali L, Benassi R, Rivasi F, et al.: Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood-brain barrier. Nanomedicine (Lond) 2011, 6:423-436.
• [36]Jain PK, Lee KS, El-Sayed IH, El-Sayed MA: Calculated absorption and scattering properties of gold nanoparticles of different size, shape, and composition: applications in biological imaging and biomedicine. J Phys Chem B 2006, 110:7238-7248.
• [37]Turkevich J, Stevenson PC, Hillier J: A study of the nucleation and growth processes in the synthesis of colloidal gold. Discuss Faraday Soc 1951, 11:55.
• [38]Gref R, Lück M, Quellec P, Marchand M, Dellacherie E, Harnisch S, et al.: “Stealth” corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B: Biointerfaces 2000, 18:301-313.
• [39]Moghimi SM, Hunter AC, Murray JC: Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001, 53:283-318.
• [40]Yuan W, Li G, Gil ES, Lowe TL, Fu BM: Effect of surface charge of immortalized mouse cerebral endothelial cell monolayer on transport of charged solutes. Ann Biomed Eng 2010, 38:1463-1472.